Furthermore, as regards the individual GLP-1 RAs, we found their patient numbers were quite limited, especially for lixisenatide and semaglutide, which have been reimbursed for T2D management in Taiwan since 2019 and 2020, respectively. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.